Study | Number of patients (M/F) | Mean age (SD) | Interventions | Background therapy | ||
---|---|---|---|---|---|---|
Treatment | Control | Treatment | Control | |||
Lavalle-González et al., 2013 [33] | 1101 (705/396) | 549 (266/283) | 55.4 (9.3) | 54.7 (9.7) | Canagliflozin (100/300 mg)/Placebo and Sitagliptin | Metformin |
Cefalu et al., 2013 [34] | 968 (493/475) | 482 (238/244) | 58.9 (9.4) | 56.3 (9.0) | Canagliflozin (100/300Â mg)/Glimepiride | Metformin |
NCT01106690, 2013 | 227 (140/87) | 115 (76/39) | 56.9 (10.3) | 58.3 (9.6) | Canagliflozin (100/300Â mg)/Placebo and Sitagliptin | Metformin and pioglitazone |
Yale et al., 2014 [35] | 179 (106/73) | 90 (57/33) | 68.7 (8.2) | 68.2 (8.4) | Canagliflozin (100/300Â mg)/Placebo | Accordance with local guidelines |
Neal et al., 2015 [20] | 2886 (1903/983) | 1441 (955/486) | 62.2 (8.1) | 62.3 (7.9) | Canagliflozin (100/300Â mg)/Placebo | Sulfonylurea |
Bode et al., 2015 [36] | 477 (253/224) | 237 (143/94) | 64.3 (6.3) | 63.2 (6.2) | Canagliflozin (100/300Â mg)/Placebo | Stable antihyperglycemic (AHA) regimen |
Rosenstock et al., 2016 [37] | 949 (453/496) | 237 (116/121) | 54.9 (9.9) | 55.2 (9.8) | Canagliflozin (100/300Â mg)/Metformin | Metformin |
NCT01989754, 2017 | 2904 (1851/1053) | 2903 (1792/1111) | 63.9 (8.4) | 64 (8.3) | Canagliflozin (100Â mg 13Â weeks then 300Â mg)/Placebo | Accordance with local guidelines |
Perkovic et al., 2019 [23] | 2200 (1438/762) | 2197 (1465/732) | 62.9 (9.2) | 63.2 (9.2) | Canagliflozin (100Â mg)/ Placebo | Accordance with local guidelines |
Lingvay et al., 2019 [38] | 394 (201/193) | 392 (221/171) | 57.5 (10.7) | 55.7 (11.1) | Canagliflozin (100Â mg 13Â weeks then 300Â mg)/Semaglutide | Metformin |
Nauck et al., 2011 [39] | 406 (227/179) | 408 (227/181) | 58.1 (9.4) | 58.6 (9.8) | Dapagliflozin (not mentioned)/Glipizide | Metformin |
Strojek et al., 2011 [40] | 450 (217/233) | 146 (72/74) | 59.7 (9.4) | 60.3 (10.2) | Dapagliflozin (2.5/5/12Â mg)/Placebo | Glimepiride |
Henry et al., 2012 [41] | 827 (657/170) | 409 (314/95) | 51.5 (10.3) | 52.3 (10.1) | Dapagliflozin (5/10Â mg)/Metformin | Metformin |
Bailey et al., 2013 [42] | 409 (216/193) | 137 (76/61) | 54 (NA) | 53.7 (NA) | Dapagliflozin (2.5/5/10Â mg)/Placebo | Metformin |
Leiter et al., 2014 [43] | 482 (323/159) | 483 (324/159) | 63.9 (7.6) | 63.6 (7.0) | Dapagliflozin (10Â mg)/Placebo | Usual care |
NCT01137474, 2014 | 633 (358/275) | 311 (171/140) | NA (NA) | NA (NA) | Dapagliflozin (2.5/5/10Â mg)/Placebo | OAD with or without insulin |
Wilding et al., 2014 [44] | 610 (290/320) | 197 (99/98) | 59.8 (8.1) | 58.8 (8.6) | Dapagliflozin (2.5/5/10Â mg)/Placebo | Insulin |
Cefalu et al., 2015 [21] | 460 (314/146) | 462 (318/144) | 62.8 (7.0) | 63 (7.7) | Dapagliflozin (10Â mg)/Placebo | Stable background treatment except rosiglitazone |
Bailey et al., 2015 [45] | 410 (198/212) | 75 (31/44) | NA (NA) | 52.7 (10.3) | Dapagliflozin (2.5/5/11Â mg)/Placebo | Metformin |
Matthaei et al., 2015 [46] | 109 (47/62) | 109 (61/48) | 61.1 (9.7) | 60.9 (9.2) | Dapagliflozin (10Â mg)/Placebo | Metformin and sulfonylurea |
Müller-Wieland et al., 2018 [47] | 313 (201/112) | 312 (207/105) | 57.4 (9.4) | 58.6 (8.4) | Dapagliflozin (13 mg)/Glimepiride | Metformin |
Scott et al., 2018 [48] | 306 (186/120) | 307 (169/138) | 66.6 (8.6) | 67.7 (8.5) | Dapagliflozin (5Â mg titrated to 10Â mg)/Sitagliptin plus Placebo Dapagliflozin | Metformin with or without sulfonylurea |
Fioretto et al., 2018 [49] | 160 (91/69) | 161 (91/70) | 65.3 (6.2) | 66.2 (6.5) | Dapagliflozin (12Â mg)/Placebo | Insulin, metformin, sulfonylurea or TZD |
Yang et al., 2018 [50] | 139 (66/73) | 133 (64/69) | 56.5 (8.4) | 58.6 (8.9) | Dapagliflozin (10Â mg)/Placebo | Insulin |
Wiviott et al., 2019 [19] | 8574 (5403/3171) | 8569 (5319/3250) | 63.9 (6.8) | 64 (6.8) | Dapagliflozin (10Â mg)/Placebo | Current background therapy |
Häring et al., 2013 [51] | 1042 (568/474) | 431 (227/204) | 55.4 (9.9) | 56 (9.7) | Empagliflozin (10/25 mg)/Placebo | Metformin or sulfonylurea |
Ferrannini et al., 2013 [52] | 547 (277/270) | 112 (57/55) | 58.9 (8.6) | 57.6 (9.8) | Empagliflozin (10Â mg)/Sitagliptin and Metformin | Metformin |
Barnett et al., 2014 [53] | 419 (249/170) | 319 (181/138) | 63.7 (8.9) | 64.1 (8.7) | Empagliflozin (10/25Â mg)/Placebo | Metformin, insulin or sulfonylurea |
Rosenstock et al., 2014 [54] | 375 (181/194) | 188 (75/113) | 57.4 (9.1) | 55.3 (10.1) | Empagliflozin (10/25Â mg)/Placebo Empagliflozin 10Â mg plus Placebo Empagliflozin 25Â mg | Insulin or metformin |
Zinman et al., 2015 [18] | 4687 (3336/1351) | 2333 (1680/653) | 63 (8.6) | 63.2 (8.8) | Empagliflozin (10/25Â mg)/Placebo | Current background therapy |
Roden et al., 2015 [55] | 1325 (765/560) | 877 (486/391) | 56 (10.3) | 55.7 (10.0) | Empagliflozin (10/25Â mg)/Placebo and Sitagliptin | Metformin, sulfonylureas |
NCT01649297, 2015 | 876 (483/393) | 107 (55/52) | 57.6 (10.2) | 57.9 (11.2) | Empagliflozin (5/12.5Â mg BID, 10/25Â mg QD)/ Placebo | Metformin |
Rosenstock et al., 2015 [56] | 324 (186/138) | 170 (90/80) | 59.2 (10.2) | 58.1 (9.4) | Empagliflozin (10/25Â mg)/Placebo | Insulin |
Araki et al., 2015 [57] | 273 (195/78) | 63 (47/16) | 61.6 (9.8) | 60 (10.2) | Empagliflozin (10/25Â mg)/Metformin and Sulfonylurea | Sulfonylurea, biguanide, TZD, AGI or DPP-4 |
Hadjadj et al., 2016 [58] | 1019 (593/426) | 341 (187/154) | 52.6 (11.0) | 52.5 (10.9) | Empagliflozin (5/12.5Â mg BID, 10/25Â mg QD)/ Metformin | Metformin |
Ridderstråle et al., 2018 [59] | 765 (432/333) | 780 (421/359) | 56.2 (10.3) | 55.7 (10.4) | Empagliflozin (25 mg)/Glimepiride plus Placebo Empagliflozin | Metformin |
Rodbard et al., 2019 [60] | 410 (209/201) | 411 (206/205) | 58 (10.0) | 57 (10.0) | Empagliflozin (25Â mg)/Semaglutide | Accordance with local guidelines |
Pratley et al., 2018 [61] | 498 (261/237) | 247 (154/93) | 55.1 (9.8) | 54.8 (10.7) | Ertugliflozin (5/15Â mg)/Sitagliptin | Metformin |
Rosenstock et al., 2018 [62] | 412 (190/222) | 209 (98/111) | 56.7 (8.8) | 56.5 (8.7) | Ertugliflozin (5/15Â mg)/Placebo plus Glimepiride | Glimepiride or insulin |
Grunberger et al., 2018 [63] | 313 (159/154) | 154 (72/82) | 67.1 (8.4) | 67.5 (8.9) | Ertugliflozin (5/15Â mg)/Placebo | Exception of metformin, rosiglitazone, and other SGLT2 inhibitors |
Dagogo-Jack et al., 2018 [64] | 309 (163/146) | 153 (100/53) | 59.4 (9.0) | 58.3 (9.2) | Ertugliflozin (5/15Â mg)/Placebo | Metformin or sitagliptin |
Hollander et al., 2019 [65] | 880 (409/471) | 435 (222/213) | 58.4 (9.8) | 57.8 (9.2) | Ertugliflozin (5/15Â mg)/Glimepiride | Metformin |
Cannon et al., 2020 [22] | 5493 (3860/1633) | 2745 (1901/844) | 64.4 (8.1) | 64.4 (8.0) | Ertugliflozin (5/15Â mg)/Placebo | Insulin, metformin and sulfonylurea |